Research Ethics Committee Reference Number Integrated Research Application System Number Submission Type Name of Trial First Patient Recruited? Date of First Patient Recruited Invited Selected Approval Date Confirmed By Confirmed Non- Confirmation Status A - Permissions Ready B - Suspended C - Closed D - delayed/ To Start by sponsor by sponsor Delays denied E - Staff availability issues F - No patients seen G - No patients consented H - Contracting delays I - Rare diseases J - Other Reasons for delay correspond to: 17/LO/0005 167346 16/LO/1502 178292 16/SC/0271 187103 PAPAYA - A phase I study of the anti-pd1 immune checkpoint inhibitor pembrolizumab in combination with radical Chemoradiotherapy in cervix cancer CTC-STOP: Utilising Circulating Tumor Cell (CTC) Counts to Optimise Systemic Therapy of Metastatic Prostate Cancer. plasmamatch - A multiple parallel cohort, nonrandomised, open label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctdna screening No 30/03/2017 04/09/2017 04/07/2017 04/09/2017 08/09/2017 Yes 15/02/2017 05/10/2016 18/10/2016 07/10/2016 12/12/2016 05/01/2017 11/01/2017 Y Y Yes 18/01/2017 26/09/2016 23/11/2016 21/09/2016 17/11/2016 12/12/2016 15/12/2016 16/EE/0305 190307 16/LO/1605 201385 16/WM/0363 189180 PRIMETIME: Post-operative avoidance of Radiotherapy In Minimal risk women: Translational biomarker implementation Hyper: A Phase 1, Dose Escalation Study Of SGI- 110, A Second Generation Hypo-Methylating Agent In Combination With Pembrolizumab (MK3475) In Patients With Refractory Solid PASART 2: Phase II clinical study of concurrent PAzopanib for non metastatic SArcoma patients to be treated with RadioTherapy, localized in the extremities, trunk and chest wall or the head and neck region. Yes 07/06/2017 23/06/2016 03/02/2017 03/11/2016 17/03/2017 20/04/2017 06/06/2017 Y Y Yes 31/01/2017 10/11/2016 05/12/2016 20/10/2016 20/12/2016 20/12/2016 20/12/2016 Yes 16/02/2017 07/12/2015 31/01/2017 05/12/2016 13/12/2016 31/01/2017 31/01/2017 17/LO/0263 211557 16/LO/1245 197327 16/LO1566 203161 ACE: Proof of concept Phase I/II trial of the CXCR2 antagonist AZD5069, administered in combination with enzalutamide, in patients with metastatic castration resistant prostate cancer(mcrpc) The HeartSpare Plus 1B Trial: A randomised phase II trial comparing the resource impact, acute toxicity, and feasibility of different panlymph node radiotherapy techniques in breast cancer KORTUC-Phase I run in study plus randomised phase II trial testing intra-tumoural hydrogen peroxide as a radiation sensitizer in women with locally advanced/recurrent breast cancer in terms of toxicity and tumour response No 12/06/2017 19/06/2017 18/04/2017 21/06/2017 21/07/2017 25/07/2017 Y Y Yes 12/01/2016 05/10/2016 05/10/2016 19/10/2016 19/10/2016 08/11/2016 12/12/2016 Yes 06/02/2017 28/06/2016 09/12/2016 09/12/2016 18/01/2017 19/01/2017 19/01/2017 17/LO/0064 198058 A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator s Choice of Chemotherapy in Women with Folate Receptor α positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Yes 25/07/2017 11/02/2016 22/05/2017 27/06/2017 12/07/2017 20/07/2017 25/07/2017 16/LO/1180 199224 13/EM/0462 136755 16/LO/1199 198197 17/LO/0378 211599 16/LO/1779 212853 16/LO/1637 211258 A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA ) VERSUS SUNITINIB (SUTENT ) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENALCELL CARCINOMA RomiCar: Phase I/II study to determine the MTD and overall response rate of the combination of romidepsin and carfilzomib in relapsed / refractory peripheral T-cell lymphoma A Global Multicenter Study of Nivolumab in Subjects with Refractory Malignancies with Microsatellite Instability High and Mismatch Repair Deficiency Peri-operative Immuno-Chemotherapy in Operable oesophageal and gastric Cancer (ICONIC Trial) A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone) First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axlspecific antibody-drug conjugate (HuMax -AXL- ADC) in patients with solid tumors Yes 13/04/2017 30/10/2016 22/11/2016 18/11/2016 25/11/2016 28/11/2016 29/03/2017 Y No 17/02/2016 20/01/2017 14/12/2016 16/03/2016 23/05/2017 02/10/2017 Y Y Yes 06/01/2016 24/11/2016 09/11/2016 24/11/2016 30/11/2016 02/12/2016 08/12/2016 No 19/12/2016 16/06/2017 21/06/2017 17/03/2017 29/06/2017 13/07/2017 Y No 21/06/2016 11/01/2017 05/01/2017 19/12/2016 11/01/2017 12/09/2017 Y Yes 29/06/2016 14/11/2016 08/11/2016 17/11/2016 21/11/2016 22/11/2016 23/11/2016 16/LO/1653 211863 Safety and Pharmacokinetics of ODM-207 in Patients with Selected Advanced Solid Tumours: An Open-Label, Non-Randomised, Uncontrolled, Multicentre, First-in-Human Study with Cohort Expansion Yes 13/02/2017 02/09/2016 19/12/2016 12/12/2016 19/01/2017 19/01/2017 20/01/2017 16/LO/1782 213379 16/LO/1784 211244 Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration- Resistant Prostate Cancer (mcrpc) (KEYNOTE- 365) A Novel Phase I/IIa Open-label Study of IMM- 101 in Combination with Selected Standard of Care (SOC) Regimens in Patients with Metastatic or Unresectable Cancer at Study Entry Yes 01/02/2017 20/07/2016 23/11/2016 29/11/2016 23/01/2017 26/01/2017 30/01/2017 No 03/11/2016 09/02/2017 13/12/2016 07/04/2017 13/04/2017 28/04/2017 Y Y
17/LO/0017 213632 16/LO/1701 198559 16/EM/0408 211983 A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study A Phase 1b (Open Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating the Efficacy of Gemcitabine and Docetaxel With or Without a Human Anti-PDGFRa Monoclonal Antibody (Olaratumab) in the Treatment of Advanced Soft Tissue Sarcoma A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined with Nivolumab versus Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Yes 03/08/2017 12/08/2016 27/04/2017 08/03/2017 07/06/2017 20/06/2017 01/08/2017 Y Yes 17/08/2017 31/01/2016 18/10/2016 17/11/2016 26/06/2017 04/07/2017 03/08/2017 Y Yes 18/01/2017 03/04/2016 05/12/2016 02/12/2016 14/12/2016 20/12/2016 23/12/2016 16/LO/1648 210861 15/NW/0517 188554 16/EM/0320 208246 16/LO/1777 211856 16/WM/0437 206855 16/LO/2043 212194 17/LO/0018 217622 A Phase III Randomized, Open-label, Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a Firstline Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mrcc) (KEYNOTE-426) A phase III study to determine the role of ixazomib as an Augmented Conditioning therapy in salvage autologous stem A RANDOMIZED, MULTICENTER, DOUBLE- BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB- PLACEBO IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB AND TAXANE BASED THERAPY. A Single-Arm, Open-Label, Multicenter, Extended Treatment, Safety Study in Patients Treated with Talazoparib A Phase 3 Multicenter, Open-label, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab versus (Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivolumab clinical Trial Evaluation 649) A Phase 1/1b Multicenter, Open-Label, Dose- Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI3726 in Subjects with Metastatic Castration Resistant Prostate Cancer (mcrpc) who have Received Prior Treatment with Abiraterone or Enzalutamide Yes 22/09/2017 16/09/2016 03/10/2016 19/12/2016 11/01/2017 23/02/2017 01/03/2017 Y Y Y Yes 06/06/2017 12/09/2016 28/03/2017 27/10/2016 07/04/2017 07/04/2017 26/04/2017 Yes 18/04/2017 19/04/2016 21/11/2016 15/11/2016 22/12/2016 17/01/2017 01/03/2017 Y Y Yes 26/01/2017 28/09/2016 11/01/2017 05/12/2016 10/01/2017 16/01/2017 18/01/2017 Yes 05/09/2017 06/10/2016 03/11/2016 16/12/2016 20/02/2017 28/02/2017 02/03/2017 Y Y Yes 10/10/2017 17/07/2017 17/07/2017 07/04/2017 31/07/2017 08/08/2017 09/08/2017 Y Yes 10/05/2017 24/08/2016 17/03/2017 17/03/2017 10/04/2017 11/04/2017 18/04/2017 17/LO/0399 218564 16/SC/0640 209571 16/LO/2137 213269 16/EE/0463 214371 The Use of 3D Surface Imaging to Simulate Outcomes after Breast Conserving Therapy Phase Ib, open-label, multi-center study to characterise the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with LCL161, everolimus (RAD001) or panobinostat (LBH589) A Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects with Select Advanced Solid An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2- negative (HER2-) advanced breast cancer (ABC) with no prior hormonal therapy for advanced disease Yes 11/05/2017 07/02/2017 02/03/2017 24/02/2017 17/03/2017 29/03/2017 04/05/2017 Yes 03/04/2017 03/11/2016 06/03/2017 25/01/2017 13/03/2017 14/03/2017 21/03/2017 Yes 05/09/2017 28/11/2016 10/07/2017 15/02/2017 24/07/2017 04/08/2017 25/08/2017 Yes 07/04/2017 13/09/2016 23/02/2017 30/01/2017 16/03/2017 21/03/2017 06/04/2017 16/NE/0316 207651 17/LO/0249 220398 17/LO/0065 219950 An Open-Label Phase 1 Study to Investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults With Steroid-Resistant Acute Graft Versus Host Disease A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION- RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN A phase III randomized, double-blind study comparing the combination of PDR001, dabrafenib and trametinib to the combination of dabrafenib and trametinib as first line therapy in patients with unresectable or metastatic BRAF V600 mutant melanoma with elevated LDH No 27/09/2016 08/02/2017 12/12/2016 Y sponsor declined site confirmation No 05/01/2017 08/02/2017 28/04/2017 25/08/2017 05/09/2017 07/09/2017 Y Yes 02/02/2017 14/02/2017 14/02/2017 20/03/2017 23/03/2017 31/03/2017 06/04/2017 17/EE/0128 222308 A Multi-Center, Open-Label Trial Investigating the Efficacy and Safety of Continued Treatment with Tisotumab Vedotin in Patients with Solid Known to Express Tissue Factor Yes 29/08/2017 02/02/2017 09/06/2017 19/05/2017 24/07/2017 04/08/2017 15/08/2017 Y
17/LO/1054 214080 17/LO/0985 211576 A phase IB open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprivation therapy and other agents in subjects with castrate-resistant prostate cancer (CRPC) A phase II study of the anti-pdl1 antibody atezolizumab, bevacizumab and acetylsalicylic acid to investigate safety and efficacy of this combination in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma No 23/11/2016 19/09/2017 30/08/2017 20/09/2017 26/09/2017 No 06/02/2017 10/08/2017 01/09/2017 13/09/2017 14/09/2017 17/LO/0591 218516 An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and/or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas Yes 15/08/2017 28/06/2017 28/06/2017 18/07/2017 07/07/2017 19/07/2017 20/07/2017 17/LO/0660 220636 17/NE/0058 219540 15/EE/0073 155221 17/LO/1068 224973 An Open-Label Multicenter Phase 1 Study of E7386 in Subjects with Selected Advanced Neoplasms A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-pd-1 Monoclonal Antibody, in Patients with Advanced Solid A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN ADULT MALE PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC, PREVIOUSLY UNTREATED, METASTATIC CASTRATE-RESISTANT PROSTATE CANCER Yes 26/07/2017 04/05/2017 30/05/2017 15/06/2017 05/07/2017 13/07/2017 19/07/2017 No 18/11/2016 22/05/2017 13/04/2017 21/06/2017 05/07/2017 15/07/2017 Y Y No 28/02/2017 13/03/2017 15/06/2016 17/05/2017 01/06/2017 14/08/2017 Y No 03/03/2017 26/09/2017 27/07/2017 28/09/2017 05/10/2017 12/10/2017 17/NW/0162 220300 17/YH/0022 215854 Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) or with Lenalidomide plus R-CHOP (R2 CHOP) in Subjects With Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma Yes 16/08/2017 02/11/2016 25/04/2017 11/05/2017 16/06/2017 26/06/2017 30/06/2017 Y Y No 04/01/2017 17/08/2017 25/07/2017 21/09/2017 26/09/2017 27/09/2017 16/SC/0231 201464 A PHASE 1B/2 OPEN-LABEL, RANDOMIZED STUDY OF 2 COMBINATIONS OF ISOCITRATE DEHYDROGENASE (IDH) MUTANT TARGETED THERAPIES PLUS AZACITIDINE: ORAL AG-120 PLUS SUBCUTANEOUS AZACITIDINE AND ORAL AG- 221 PLUS SC AZACITIDINE IN SUBJECTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA HARBORING AN IDH1 OR AN IDH2 MUTATION, RESPECTIVELY, WHO ARE NOT CANDIDATES TO RECEIVE INTENSIVE INDUCTION CHEMOTHERAPY No 22/03/2017 10/04/2017 23/09/2016 30/06/2017 07/07/2017 10/07/2017 Y Y 17/SW/0078 222659 A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915: CHECKpoint pathway and nivolumab clinical Trial Evaluation 915) Yes 04/08/2017 23/03/2017 01/06/2017 05/06/2017 14/06/2017 20/06/2017 02/08/2017 17/LO/0927 224022 A Phase 2, Multicenter, International, Open- Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) No 15/03/2017 22/09/2017 26/07/2017 19/09/2017 26/09/2017 24/10/2017 15/NE/0415 189037 A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-hodgkin s lymphoma (inhl) - CHRONOS-4 No 16/01/2017 24/08/2017 20/01/2016 12/09/2017 25/09/2017 17/LO/0023 215490 MUK nine b: OPTIMUM. A phase II study evaluating optimised combination of biological therapy in newly No 21/09/2016 08/05/2017 30/03/2017 31/07/2017 15/09/2017 02/10/2017 Y Y diagnosed high risk multiple myeloma and plasma cell leukaemia. 17/SC/0253 226685 MonarchE: Protocol I3Y-MC-JPCF A Randomized, No 13/03/2017 13/07/2017 13/07/2017 09/08/2017 30/08/2017 01/09/2017 Y Y
14/LO/1273 216265 A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic previously Untreated Esophageal Squamous Cell Carcinoma (CheckMate 648: CHECKpoint pathway and nivolumab clinical Trial Evaluation 648) No 07/03/2017 18/09/2017 30/08/2017 22/09/2017 20/10/2017 24/10/2017 17/SW/0011 219530 17/NW/0312 211974 17/YH/0182 227570 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma Phase II study of cabozantinib in patients with metastatic gastrointestinal stromal tumor (GIST) who progressed during neoadjuvant, adjuvant or palliative therapy with imatinib and sunitinib. A Phase 1/2, open-label, multicentre, dose escalation and dose expansion study of NKTR- 214 and Nivolumab in patients with select locally advanced or metastatic solid tumor malignancies No 15/02/2017 11/07/2017 23/05/2017 31/07/2017 31/07/2017 Y Yes 05/10/2017 15/05/2017 22/05/2017 13/07/2017 10/08/2017 15/08/2017 01/09/2017 Y Y No 05/09/2016 31/08/2017 10/07/2017 21/09/2017 27/09/2017 02/10/2017 17/LO/1347 229728 17/EM/0272 228700 A Phase 1/1b Study of Paclitaxel in Combination with BOS172722, a Monopolar Spindle 1 Kinase Inhibitor, in Patients with Advanced Nonhaematologic Malignancies ElevatION:CRC-101: A Phase Ib study of PDR001 in combination with bevacizumab and mfolfox6 as first line therapy in patients with metastatic MSS colorectal cancer No 14/06/2017 19/09/2017 06/10/2017 03/10/2017 12/10/2017 No 15/05/2017 07/09/2017 04/09/2017 08/09/2017 11/09/2017 14/09/2017 17/EM/0152 216307 17/EE/0317 230053 15/NI/0161 184748 16/LO/1686 202638 A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML A Phase 1, Open-Label, Multicentre, Non- Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD4573, a Potent and Selective CDK9 Inhibitor, in Subjects with Relapsed or Refractory Haematological Malignancies Early switch to oral antibiotic therapy in patients with low risk neutropenic sepsis BARCODE 2 - Targeting cancer care with the use of genetic profiling No 09/12/2016 25/07/2017 21/07/2017 No 27/09/2017 27/09/2017 No 04/01/2017 16/05/2017 03/08/2016 19/06/2017 26/06/2017 17/07/2017 Y Y Yes 25/10/2016 27/03/2017 21/04/2017 02/05/2017 05/05/2017 25/05/2017 25/05/2017 16/EM/0240 203358 16/LO/2186 188540 A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B- cell non-hodgkin Lymphoma A randomised phase I/II study of Intensity Modulated Arc Therapy techniques in abdominal neuroblastoma No 08/03/2016 11/10/2016 11/10/2016 16/02/2017 04/05/2017 21/07/2017 Y Yes 24/01/2017 24/01/2017 17/01/2017 17/02/2017 15/02/2017 22/02/2017 22/02/2017 15/EM/0323 76077 17/SC/0406 217627 LCH- IV International Collaborative Treatment Proto col for Children and Adolescents with Langerhans Cell Histiocytosis COMET Concordance in MRI and Pathology Diagnosis of Extranodal Tumour Deposits No 08/02/2017 24/04/2017 19/07/2016 16/03/2017 14/06/2017 04/07/2017 Y Y Yes 21/07/2017 22/09/2017 05/10/2017 05/09/2017 12/10/2017 16/10/2017 18/10/2017 16/LO/2141 200571 Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (Biomede) No 23/02/2017 10/04/2017 06/04/2017 05/07/2017 31/07/2017 20/10/2017 Y 17/WM/0110 212527 15/LO/1835 111728 15/LO/1464 174042 Paediatric Hepatic International Tumour Trial An international prospective study on clinically standard risk medulloblastoma in children older than 3 years with lowrisk biological profile (PNET 5 MB LR) or average risk biological profile (PNET 5 MB SR) SIOP PNET 5 Medulloblastoma DARS: a phase III randomised multicentre study of dysphagia optimized intensity modulated radiotherapy (Do-IMRT) versus standard intensity modulated radiotherapy (s-imrt) in head and neck cancer Yes 20/10/2017 13/06/2017 19/07/2017 28/04/2017 21/07/2017 25/09/2017 28/09/2017 Y Y No 20/07/2017 27/07/2017 20/10/2016 24/08/2017 21/09/2017 Yes 24/05/2017 28/09/2016 30/11/2016 15/06/2016 20/12/2016 04/01/2017 15/03/2017 Y 07/Q0703/24 146682 Improving Outcomes in Robotic and Endoscopic Surgery using Augmented Reality Guidance Yes 20/01/2017 26/03/2015 30/12/2016 30/12/2016 03/03/2016 04/01/2017 10/01/2017 16/LO/1640 196800 Assessing the accuracy of lung radiotherapy using fiducial markers for verification during fractionated external beam radiotherapy. No 14/07/2016 16/12/2016 03/04/2017 11/04/2017 20/04/2017 Y 16/NE/0419 202460 16/WM/0010 169512 A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after chemo-radiotherapy A phase II trial of pembrolizumab in patients with non-small cell lung cancer and a performance status of 2 No 14/10/2015 21/04/2017 13/04/2017 13/04/2017 03/05/2017 09/05/2017 Y Y Yes 10/06/2016 03/10/2016 29/06/2016 17/10/2016 03/11/2016 08/11/2016 17/11/2016 16/SC/0484 208568 An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + Cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Yes 03/04/2017 29/09/2016 07/12/2016 10/02/2017 23/02/2017 23/02/2017 24/02/2017 Y Y 16/LO/1940 213099 AN OPEN LABEL, SINGLE ARM, MULTICENTER, SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT Yes 12/05/2017 19/10/2016 07/11/2016 12/01/2017 09/03/2017 05/04/2017 11/04/2017 Y Y
16/LO/1697 212844 16/EM/0165 203281 15/WM/0392 180166 A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum- Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma A Phase 3 Multicenter Open-label Study of Brigatinib versus Crizotinib Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. A randomised phase III trial. No 07/11/2016 23/11/2016 11/11/2016 21/08/2017 04/09/2017 Y Yes 05/04/2016 28/03/2017 12/07/2016 22/05/2017 30/05/2017 09/06/2017 31/05/2017 Y Y No 06/10/2016 23/11/2016 27/05/2016 Y 16/EE/0446 214004 A Phase 2 Efficacy and Safety Study of Niraparib in men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies Yes 30/03/2017 14/10/2016 17/11/2016 04/01/2017 22/03/2017 27/03/2017 29/03/2017 Y 16/LO/1799 199959 An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) Yes 29/03/2017 19/10/2016 15/03/2017 12/12/2016 16/03/2017 20/03/2017 22/03/2017 17/SC/0028 218036 17/EE/0021 218207 A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) (CheckMate 714) Phase I Open Label, Multicenter Study of MK- 1454 Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab for Patinets with Advanced/Metastatic Solid or Lymphomas Yes 13/04/2017 02/11/2016 01/03/2017 09/02/2017 29/03/2017 03/04/2017 04/04/2017 Yes 13/07/2017 02/02/2017 13/04/2017 27/03/2017 11/05/2017 18/05/2017 13/07/2017 Y 17/LO/0339 219974 A randomized phase III study of pembrolizumab given concomitantly to chemoradiation and as maintenance therapy versus chemoradiation alone in patients with locally advanced squamous cell carcinoma of the head and neck No 20/03/2017 04/08/2017 18/04/2017 27/09/2017 06/10/2017 06/10/2017 17/LO/0425 222355 17/SC/0231 221097 16/LO/2195 219516 AN EXPLORATORY TUMOR BIOPSY-DRIVEN STUDY TO UNDERSTAND THE RELATIONSHIP BETWEEN BIOMARKERS AND CLINICAL RESPONSE IN IMMUNOMODULATORY TREATMENT-NAIVE PATIENTS WITH RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK RECEIVING REGN2810 (ANTI-PD-1) A multicentre randomised phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency Yes 31/08/2017 23/01/2017 31/05/2017 11/04/2017 20/07/2017 24/07/2017 03/08/2017 Y Y Yes 05/09/2017 03/03/2017 10/05/2017 27/06/2017 14/06/2017 03/07/2017 04/09/2017 Y Y No 11/05/2017 09/08/2017 28/03/2017 15/08/2017 24/08/2017 25/08/2017 16/NE/0353 211988 A randomized, double-blind, placebo-controlled Phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer No 16/05/2017 12/06/2017 19/12/2016 05/09/2017 14/09/2017 26/09/2017 Y 16/SC/0376 202786 Testing Radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility trial No 07/08/2017 17/08/2017 10/10/2016 15/SS/0225 169859 A randomised phase II trial of standard versus dose escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma Yes 04/09/2017 04/11/2016 22/02/2017 05/10/2016 06/04/2017 20/04/2017 27/04/2017 Y Y